Tags : Rights

Animal Health

Merck Animal Health to Acquire Rights to Sentinel Brand of

Shots: Merck Animal Health to acquire the US rights to Sentinel flavor tabs and chews in the companion animal category, under the agreement with Virbac. The transaction is expected to be closed by mid-2020 With the acquisition, Merck expects to provide veterinarians continuous parasite protection for dogs in easy to administer, palatable formulations The products […]Read More


Elevar Therapeutics Acquires Worldwide Development and Commercialization Rights for Oasmia’s

Shots: Elevar to receive $20M up front, ~$678M as milestones based on the company’s achievement regarding the product along with royalties on sales of Apealea globally excluding Nordics, Russia, and certain countries in Eastern Europe The agreement allows Elevar the right to sub-license Apealea to other partners in the EU. Elevar will be responsible for […]Read More


Daiichi Sankyo to Return Exclusive Development and Commercialization Rights for

Shots: Daiichi to return rights for four diagnostic imaging agents to GE Healthcare Omnipaque, Omniscan, including Visipaque, Sonazoid and the transfer of marketing authorization rights is expected to be complete in Mar’2020 GE Healthcare will be responsible for commercialization & regulatory activities for all four imaging agents. Daiichi will hold the rights to distribute the […]Read More